C1q activators constitute a diverse array of chemical entities that are characterized by their ability to enhance the functional activity of the C1q protein, a key component of the classical complement pathway. C1q is primarily recognized for its role in the immune system where it binds to the Fc region of antibodies that are attached to pathogens, triggering a series of immune responses that include the opsonization of pathogens and the initiation of a complement cascade resulting in the formation of a membrane attack complex. Activators of C1q can operate through various mechanisms, with some directly binding to the C1q molecule itself, thereby stabilizing its conformation and enhancing its ability to initiate the complement cascade. Others may work by upregulating the cellular pathways that lead to the expression and stabilization of C1q or its receptor interactions, which are essential for its proper functioning in the immune response. These chemicals, while diverse in structure, share the common feature of promoting the activity of C1q without necessarily increasing its expression.
The biochemical activation mechanisms of C1q activators can be quite intricate. Some activators may influence the configuration of C1q, facilitating its interaction with the C1r2s2 complex, which is a crucial step in the activation of the classical pathway. Other compounds may interact with various regulators of complement activation, such as C1 inhibitor (C1-INH), to sustain a favorable balance that promotes C1q function. By influencing the proteases that cleave and activate downstream components of the complement system, such as C4 and C2, these activators indirectly bolster the function of C1q. Although they do not directly modify the protein structure of C1q, their actions on related molecules and signaling pathways result in a net increase in the functional potential of C1q, thus enhancing its role in the immune system's defense mechanisms. Collectively, these activators work in concert to ensure that C1q can effectively fulfill its role in the recognition and clearance of pathogens, as well as in the removal of apoptotic cells, thereby maintaining homeostasis within the immune system.
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Los inhibidores de la histona desacetilasa pueden modificar la regulación epigenética de la expresión de C1q, lo que podría provocar cambios en su actividad. | ||||||
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | $112.00 $194.00 $871.00 $1538.00 | 3 | |
Compuestos como el MCC950 pueden inhibir el inflamasoma NLRP3, que puede tener efectos descendentes en la activación del complemento, incluido el C1q. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Los compuestos como BAY 11-7082 que inhiben NF-kB podrían afectar a la transcripción de los genes del sistema del complemento, incluido C1q. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
Los agonistas PPARγ podrían modular la función de los macrófagos, afectando posiblemente a la actividad de C1q de forma indirecta. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
Los moduladores del receptor de esfingosina-1-fosfato podrían influir en la salida y la función de los linfocitos, con posibles efectos secundarios en la actividad de C1q. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
El SB431542 y otros inhibidores de la vía del TGF-β podrían influir en la expresión de los componentes del complemento, incluido el C1q. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
Los compuestos que inhiben IKK podrían afectar a la señalización de NF-kB y, por tanto, influir en la expresión de C1q. | ||||||